Nomination Committee – iZafe Group

iZafe Group AB (publ.) is pleased to announce that the company's major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren. This step marks a significant milestone in enhancing corporate governance and ensuring that the company's leadership is aligned with shareholder interests and strategic objectives.

The Nomination Committee comprises the following members, representing a diverse mix of the company's ownership:

Patrik Björn, representing personal holdings through Gästrike Nord Invest AB
Stefan Wård, representing personal holdings
Marc Tarruell Tibau, representing personal holdings through Timedi S.L.
Björn Rosengren, Chairman of the Board, iZafe Group AB

Stefan Wård has been appointed as the Chairman of the Nomination Committee.

The Nomination Committee represents approximately 33% of the total number of outstanding shares and votes.

The primary responsibility of the Nomination Committee is to prepare and present proposals for the Annual General Meeting, on May 30 2024, regarding the election of the meeting's chairman, the Board of Directors, the Chairman of the Board, and auditors. The committee will also propose fees for board members and remuneration for auditors.

Shareholders in iZafe Group are encouraged to submit proposals to the Chairman of the Nomination Committee. Submissions can be made via email at or by postal mail to: iZafe Group, Attn: Nomination Committee, David Bagares Gata 3, 111 38 Stockholm, Sweden.

This initiative underscores iZafe Group's commitment to robust corporate governance practices that support the company's long-term strategy and value creation for shareholders.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group announces the appointment of nomination committee

Valberedning 2024

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – a leading Life-Science company in healthcare digitalization announces that the company's major shareholders have appointed a nomination committee. iZafe Group AB's major shareholders and group of owners have, in consultation with the Chairman of the Board, Thomas Ahlerup, appointed the following representatives to be part of the Nomination Committee:

Torgny Ander, appointed by Göran Sjönell

Sten Röing, own holding

Peter Werner, appointed by the ownership group Hermansson – Segerström

Thomas Ahlerup, Chairman of the Board, iZafe Group AB

Torgny Ander has been appointed Chairman of the Nomination Committee.

The Nomination Committee's task is to present proposals to the Chairman of the Annual General Meeting, the Board, the Chairman of the Board and auditors prior to the 2021 Annual General Meeting, as well as proposals for fees to the Board members as well as remuneration of auditors.

Shareholders in iZafe Group AB are welcome to submit proposals to the Chairman of the Nomination Committee by e-mail or by post to: iZafe Group AB, Nomination Committee, Grev Turegatan 11A, 114 46 Stockholm.

If you have any questions, please contact:
Torgny Ander:
Thomas Ahlerup:

About Us

iZafe Group is a Swedish med-tech company that develops and markets medical and digital security solutions to create safer drug handling at home. Our digital medicine dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. Our products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafegroup.com/investorrelations.

iZafe Group AB appoints the Nomination Committee